Ignacio Dallo, Riccardo D'Ambrosi, Dawid Szwedowski, Ali Mobasheri, and Alberto Gobbi. Minimally Invasive Cell-Based Therapy for Symptomatic Bone Marrow Lesions of the Knee: A Prospective Clinical Study at 1 Year. Stem Cells and Development.Aug 2022.488-497.http://doi.org/10.1089/scd.2021.0283
Minimally invasive cell-based therapy for symptomatic bone marrow lesions of the knee : a prospective clinical study at 1 year
|Author:||Dallo, Ignacio1,2; D’Ambrosi, Riccardo3; Szwedowski, Dawid1;|
1OASI Bioresearch Foundation, Gobbi NPO, Milan, Italy
2SportMe Medical Center, Unit of Biological Therapies, Sevilla, Spain
3IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
4Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania
5Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland
6Departments of Orthopedics, Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
7Department of Joint Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
8World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Aging, Universite ́de Lie`ge,Lie`ge, Belgium
|Online Access:||PDF Full Text (PDF, 0.7 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2023030930813
Mary Ann Liebert,
|Publish Date:|| 2023-03-09
Bone marrow lesions (BMLs) are typical findings in magnetic resonance imaging present in different pathologies, such as spontaneous insufficiency fractures, osteonecrosis, transient BML syndromes, osteoarthritis, and trauma. The etiology and evolution of BMLs in multiple conditions remain unclear. There is still no gold standard protocol for the treatment of symptomatic BMLs in the knee. The biologic augmentation by Osteo Core Plasty™ is a new treatment modality showing promising results reducing pain with the aim to stop the progression of the disease. The purpose of this prospective study is to report the clinical outcomes and safety of Osteo Core Plasty for the treatment of symptomatic BMLs in the knee. Fifteen patients with symptomatic BMLs of the knee treated with the Osteo Core Plasty technique were included and followed prospectively for a minimum of 12 months. Each patient was evaluated before the surgery and respectively at 6 and 12 months using the Tegner Score, Marx Score, the International Knee Documentation Committee, the Knee Injury and Osteoarthritis Outcome Score divided in pain, activity daily living and quality of life subscale, and the Visual Analog Scale for pain. All clinical scores except Tegner and Marx score showed an overall statistically significant improvement through the entire follow-up (P < 0.05) and a significant improvement (P < 0.05) between each follow-up period (T₀ vs. T₁; T₀ vs. T₂; T₁ vs. T₂). No complications were reported. These preliminary results confirm that biological subchondral bone augmentation by Osteo Core Plasty technique is a safe and effective minimally invasive treatment option for symptomatic BMLs in the knee at 1-year follow-up. There is still a need for high-quality randomized controlled trials studies and systematic reviews in the future to enhance further treatment strategies in preventing or treating BMLs of the knee.
Stem cells and development
|Pages:||488 - 497|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3121 General medicine, internal medicine and other clinical medicine
This study was funded by the OASI Bioresearch Foundation, Milan, Italy, and did not receive any external funding. A.M. has received grants, non-financial support and other from Merck KGaA; grants, non-financial support and other from Kolon TissueGene; grants, non-financial support and other from Merck KGaA; grants from Pfizer; grants from European Commission-Innovative Medicines Initiative; grants from European Union Structural Funds administered by the Research Council of Lithuania (Lietuvos mokslo taryba); grants from European Union Structural Funds administered by the Research Council of Lithuania (Lietuvos mokslo taryba); grants from European Commission-Framework 7 (FP7-HEALTH); grants from European Commission-Framework 7 (FP7-PEOPLE) Marie Skłodowska-Curie Program; personal fees from Galapagos-Servier; personal fees from Image Analysis Group; personal fees, non-financial support and other from Artialis SA; personal fees and other from Achē (Achē Laboratrios Farmaceuticos); personal fees and other from Abbvie; personal fees from Guidepoint Global; personal fees from Alphasights; personal fees from Science Branding Communications; personal fees and non-financial support from Pfizer Consumer Healthcare; non-financial support from GlaxoSmithKline (GSK) Consumer Healthcare; personal fees and other from Flexion Therapeutics; personal fees from Pacira Biosciences; other from Genacol; personal fees, non-financial support and other from Sterifarma; other from Henry Stewart Talks; non-financial support from GSK; grants from Versus Arthritis (Arthritis Research UK); personal fees and other from Korean Society for Osteoarthritis and Cartilage Repair; personal fees from American College of Rheumatology; personal fees and other from Spanish Society of Rheumatology; personal fees and other from Heilongjiang Rheumatology Association; personal fees and other from Zhujiang Hospital of Southern Medical University; non-financial support and other from International Cartilage Regeneration and Joint Preservation Society; non-financial support and other from Osteoarthritis Research Society International; non-financial support from AxDev International; other from Gordian Biotechnology; other from UNITY Biotechnology; personal fees and other from Bioiberica; other from The Dutch Arthritis Society (ReumaNederland); other from Kolon Life Science; personal fees from SANOFI; personal fees from European Commission; other from BRASIT/BRASOS, Brazil; other from GEOS, Brazil; other from European Orthopaedic Research Society; other from Brazilian Society of Rheumatology; other from Society for Osteoarthritis Research, India; other from MCI Group, Geneva outside the submitted work.
The underlying data supporting the results of this study can be found are securely maintained in the OASI Bioresearch Foundation, Milan, Italy.
© Mary Ann Liebert, Inc. This is the accepted version of the following article: Ignacio Dallo, Riccardo D'Ambrosi, Dawid Szwedowski, Ali Mobasheri, and Alberto Gobbi. Minimally Invasive Cell-Based Therapy for Symptomatic Bone Marrow Lesions of the Knee: A Prospective Clinical Study at 1 Year. Stem Cells and Development.Aug 2022.488-497, which has now been formally published in final form at Stem Cells and Development at http://doi.org/10.1089/scd.2021.0283. This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers’ self-archiving terms and conditions.